Emergence of Vibrio cholerae O1 Biotype El Tor serotype Inaba in north India. 2005

Neelam Taneja, and Manisha Biswal, and Bansidhar Tarai, and Meera Sharma
Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. drneelampgi@yahoo.com

All cases of cholera that have occurred at our center in north India have been due to Vibrio cholerae O1 serotype Ogawa, including the outbreaks in 2002 and 2004. Here we report the emergence of V. cholerae O1 biotype El Tor serotype Inaba for the first time in this region since July 2004. Fifteen Inaba isolates were obtained from 32 patients suffering from cholera-like illness. The patients lived in Chandigarh and the neighboring states of Punjab, Haryana, and Himachal Pradesh. All strains were resistant to nalidixic acid and trimethoprim, and showed moderate sensitivity to amoxycillin. All were sensitive to ciprofloxacin, tetracycline, cefotaxime, amikacin, and gentamicin. All strains were found to be toxigenic when tested with a commercial reverse passive latex agglutination kit. The last reported Inaba isolate dominance in India was observed in Calcutta in 1989. There is a need to closely watch the spread of serotype Inaba, as it may cause outbreaks in other parts of India; molecular studies are warranted to understand the widespread emergence of Inaba in north India.

UI MeSH Term Description Entries
D007194 India A country in southern Asia, bordering the Arabian Sea and the Bay of Bengal, between Burma and Pakistan. The capitol is New Delhi. Republic of India
D008297 Male Males
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009268 Nalidixic Acid A synthetic 1,8-naphthyridine antimicrobial agent with a limited bacteriocidal spectrum. It is an inhibitor of the A subunit of bacterial DNA GYRASE. Nalidixin,Nalidixate Sodium,Nalidixate Sodium Anhydrous,Nevigramon,Sodium Nalidixic Acid, Anhydrous,Sodium Nalidixic Acid, Monohydrate,Acid, Nalidixic,Anhydrous, Nalidixate Sodium,Sodium Anhydrous, Nalidixate,Sodium, Nalidixate
D002439 Cefotaxime Semisynthetic broad-spectrum cephalosporin. Benaxima,Biosint,Cefotaxim,Cefotaxime Sodium,Cefradil,Cephotaxim,Claforan,Fotexina,HR-756,Kendrick,Klaforan,Primafen,Ru-24756,Taporin,HR 756,HR756,Ru 24756,Ru24756,Sodium, Cefotaxime
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D002771 Cholera An acute diarrheal disease endemic in India and Southeast Asia whose causative agent is VIBRIO CHOLERAE. This condition can lead to severe dehydration in a matter of hours unless quickly treated. Vibrio cholerae Infection,Choleras,Infection, Vibrio cholerae,Infections, Vibrio cholerae,Vibrio cholerae Infections
D002939 Ciprofloxacin A broad-spectrum antimicrobial carboxyfluoroquinoline. Bay-09867,Ciprinol,Cipro,Ciprofloxacin Hydrochloride,Ciprofloxacin Hydrochloride Anhydrous,Ciprofloxacin Monohydrochloride Monohydrate,Anhydrous, Ciprofloxacin Hydrochloride,Bay 09867,Bay09867,Hydrochloride Anhydrous, Ciprofloxacin,Hydrochloride, Ciprofloxacin,Monohydrate, Ciprofloxacin Monohydrochloride,Monohydrochloride Monohydrate, Ciprofloxacin

Related Publications

Neelam Taneja, and Manisha Biswal, and Bansidhar Tarai, and Meera Sharma
November 2000, Journal of clinical microbiology,
Neelam Taneja, and Manisha Biswal, and Bansidhar Tarai, and Meera Sharma
August 2006, Japanese journal of infectious diseases,
Neelam Taneja, and Manisha Biswal, and Bansidhar Tarai, and Meera Sharma
January 2010, Indian journal of pathology & microbiology,
Neelam Taneja, and Manisha Biswal, and Bansidhar Tarai, and Meera Sharma
November 1991, CDR (London, England : Weekly),
Neelam Taneja, and Manisha Biswal, and Bansidhar Tarai, and Meera Sharma
September 2005, Annals of tropical paediatrics,
Neelam Taneja, and Manisha Biswal, and Bansidhar Tarai, and Meera Sharma
February 2007, Journal of medical microbiology,
Neelam Taneja, and Manisha Biswal, and Bansidhar Tarai, and Meera Sharma
June 2012, The American journal of tropical medicine and hygiene,
Neelam Taneja, and Manisha Biswal, and Bansidhar Tarai, and Meera Sharma
September 2006, Journal of clinical microbiology,
Neelam Taneja, and Manisha Biswal, and Bansidhar Tarai, and Meera Sharma
May 2012, MMWR. Morbidity and mortality weekly report,
Neelam Taneja, and Manisha Biswal, and Bansidhar Tarai, and Meera Sharma
March 2008, Japanese journal of infectious diseases,
Copied contents to your clipboard!